Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

126.76USD
25 Apr 2018
Change (% chg)

$0.57 (+0.45%)
Prev Close
$126.19
Open
$125.91
Day's High
$126.84
Day's Low
$125.29
Volume
1,851,558
Avg. Vol
2,416,940
52-wk High
$148.32
52-wk Low
$122.15

Latest Key Developments (Source: Significant Developments)

U.S. FDA Says Cleared Contact Lens To Incorporate Additive That Automatically Darkens Lens When Exposed To Bright Light
Tuesday, 10 Apr 2018 01:32pm EDT 

April 10 (Reuters) - U.S. Food & Drug Administration::U.S. FOOD & DRUG ADMINISTRATION SAYS CLEARED FIRST CONTACT LENS TO INCORPORATE ADDITIVE THAT AUTOMATICALLY DARKENS LENS WHEN EXPOSED TO BRIGHT LIGHT.U.S. FDA SAYS GRANTED CLEARANCE OF THE ACUVUE OASYS CONTACT LENSES WITH TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY TO JOHNSON & JOHNSON VISION CARE INC.  Full Article

Dominic Caruso To Retire As Chief Financial Officer Of Johnson & Johnson
Tuesday, 20 Mar 2018 04:15pm EDT 

March 20 (Reuters) - Johnson & Johnson ::DOMINIC J. CARUSO TO RETIRE AS CHIEF FINANCIAL OFFICER OF JOHNSON & JOHNSON.J&J - ‍DOMINIC J. CARUSO TO RETIRE AS CHIEF FINANCIAL OFFICER​.J&J - ‍JOSEPH WOLK PROMOTED TO EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER​.  Full Article

Janssen Announces FDA Breakthrough Therapy Designation For Erdafitinib In The Treatment Of Metastatic Urothelial Cancer
Thursday, 15 Mar 2018 08:00am EDT 

March 15 (Reuters) - Johnson & Johnson ::JANSSEN ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ERDAFITINIB IN THE TREATMENT OF METASTATIC UROTHELIAL CANCER.JANSSEN PHARMACEUTICAL - BREAKTHROUGH THERAPY DESIGNATION BASED ON DATA FROM MULTICENTER, OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ERDAFITINIB.  Full Article

J&J Says CEO Alex Gorsky's FY 2017 Total Compensation Was $29.8 Mln Vs $26.9 Mln In FY 2016
Wednesday, 14 Mar 2018 08:25am EDT 

March 14 (Reuters) - Johnson & Johnson ::J&J SAYS CHAIRMAN AND CEO ALEX GORSKY'S FY 2017 TOTAL COMPENSATION WAS $29.8 MILLION VERSUS $26.9 MILLION IN FY 2016 - SEC FILING.J&J - CFO DOMINIC CARUSO'S TOTAL COMPENSATION FOR 2017 WAS $11.7 MILLION VERSUS $11.3 MILLION IN 2016.J&J - EVP, WORLDWIDE CHAIRMAN PHARMACEUTICALS JOAQUIN DUATO'S TOTAL COMPENSATION FOR 2017 WAS $19.4 MILLION VERSUS $10.1 MILLION IN 2016.  Full Article

Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs
Tuesday, 27 Feb 2018 08:00am EST 

Feb 27 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES.ALDEYRA THERAPEUTICS INC - ‍ ENTERED INTO A COLLABORATIVE RESEARCH AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT​.ALDEYRA - ‍ AGREEMENT WITH JANSSEN TO ADVANCE DEVELOPMENT OF EXISTING ANALOGS OF REPROXALAP FOR TREATMENT OF SYSTEMIC INFLAMMATORY DISEASES​.ALDEYRA THERAPEUTICS INC - WILL COLLABORATE WITH JANSSEN ON RESEARCH ACTIVITIES, WHICH WILL BE GOVERNED BY A JOINT SCIENTIFIC REVIEW COMMITTEE​.ALDEYRA - ‍ FOR A LIMITED PERIOD, SUBJECT TO CONDITIONS, JANSSEN TO RETAIN OPTION TO NEGOTIATE EXCLUSIVE LICENSE PERTAINING TO COMPOUNDS DEVELOPED.  Full Article

FDA Approves Janssen Pharmaceutical's Erleada For A Certain Type Of Prostate Cancer
Wednesday, 14 Feb 2018 01:52pm EST 

Feb 14 (Reuters) - The U.S. Food and Drug Administration::SAYS APPROVED JANSSEN PHARMACEUTICAL'S ERLEADA FOR A CERTAIN TYPE OF PROSTATE CANCER USING NOVEL CLINICAL TRIAL ENDPOINT‍​.  Full Article

‍Janssen Submits Marketing Authorisation Application To EMA For Apalutamide
Friday, 9 Feb 2018 03:00am EST 

Feb 9 (Reuters) - :‍JANSSEN SUBMITS MARKETING AUTHORISATION APPLICATION FOR APALUTAMIDE TO TREAT PATIENTS WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER​.‍JANSSEN PHARMACEUTICAL - SUBMITTED MARKETING AUTHORISATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) FOR APALUTAMIDE​.  Full Article

Theravance Biopharma Ireland Enters Global Collaboration With Janssen
Wednesday, 7 Feb 2018 07:30am EST 

Feb 7 (Reuters) - Theravance Biopharma Ireland Limited::THERAVANCE BIOPHARMA IRELAND LTD - ENTERS GLOBAL COLLABORATION WITH JANSSEN FOR TD-1473 IN INFLAMMATORY INTESTINAL DISEASES.THERAVANCE BIOPHARMA - ELIGIBLE FOR UP TO $1 BILLION POTENTIAL PAYMENTS, INCLUDING $100 MILLION UPFRONT.THERAVANCE BIOPHARMA - PHASE 2B/3 STUDY IN ULCERATIVE COLITIS, PHASE 2 STUDY IN CROHN’S DISEASE TO BEGIN IN 2018 WITH TD-1473.THERAVANCE BIOPHARMA - WILL LEAD DEVELOPMENT OF TD-1473 IN ULCERATIVE COLITIS THROUGH COMPLETION OF PHASE 2B/3 PROGRAM.THERAVANCE BIOPHARMA - AFTER PHASE 2 CROHN’S STUDY, PHASE 2B INDUCTION PORTION OF ULCERATIVE COLITIS STUDY, JANSSEN CAN ENTER EXCLUSIVE LICENSE DEAL.THERAVANCE BIOPHARMA - AFTER PHASE 2, JANSSEN WOULD LEAD SUBSEQUENT DEVELOPMENT OF TD-1473 IN CROHN’S DISEASE.THERAVANCE BIOPHARMA - JANSSEN CAN ENTER EXCLUSIVE LICENSE DEAL FOR TD-1473 BY PAYING CO $200 MILLION FEE.THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, CO HAS OPTION TO CO-COMMERCIALIZE IN THE U.S..THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, JANSSEN WOULD HAVE SOLE COMMERCIALIZATION RESPONSIBILITIES OUTSIDE U.S..THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, CO ELIGIBLE FOR UP TO ADDITIONAL $700 MILLION DEVELOPMENT, COMMERCIALIZATION MILESTONE PAYMENTS.  Full Article

Novartis says data reinforces ‍Cosentyx effectiveness
Tuesday, 16 Jan 2018 01:15am EST 

Jan 16 (Reuters) - Novartis AG ::NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS.‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​.‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​.  Full Article

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Tuesday, 9 Jan 2018 06:30pm EST 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Photo

Kentucky accuses J&J of contributing to opioid epidemic

Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.